谷歌浏览器插件
订阅小程序
在清言上使用

(608) Could the Full Maglev Technology Be the Next Option for Pediatric Patients?

˜The œjournal of heart and lung transplantation/˜The œJournal of heart and lung transplantation(2023)

引用 0|浏览11
暂无评分
摘要
Purpose The Heartware (HVAD) and Heartmate 3 (HM3) are centrifugal continuous flow ventricular assist devices (VAD), used in adults for treatment of advanced heart failure with favorable survival outcomes to transplant. The HVAD pump has been used in many pediatric patients until last year and the results have been published. However, The company of HVAD stoped selling and distributing the this pump in last year. On the other hand little is known about the outcomes of HM3 (The Full MagLev Technology) in pediatrics. We analyzed our experience HVAD and HM3 VAD implantation in pediatric patients. Methods From June 2013 to September 2022, 43 patients under 19 years of age who underwent third-generation continuous flow centrifugal pumps implantation were included in this retrospective single-center study. Study cohort was divided into two groups according to pump. Group 1 (n = 27) HVAD Pump, Group 2 (n= 16) consisted of patients who has HM3 Pump. To compare outcomes of these pumps, measures were the length of entubation, blood loss and transfusion, intensive care unit and hospital stay, right ventricular (RV) failure and requirement support with devices, stroke, pump thrombosis, and bleending in hospital, mortality. Results There was no difference in ICU length of stay, post-operative blood transfusion, total time on mechanical ventilation, RVF, gastrointestinal bleeding, and pump thrombosis (p >0.05). Patients in the group 1 were younger, lower BMI, BSA, LVEDD, LVESD, and duration of cardiopulmonary bypass (p<0.05). There was no difference 30-days mortality. However, all mortality rate was higher in HVAD group 1 (p<0.05). The incidence of stroke was higher in the group 1 but were not statistically significant (p> 0.05). Conclusion HM3 assist system(The Full MagLev Technology) can be successfully implanted with a low incidence of mortality and adverse events in pediatric patients. Patients as small as BSA 0.7 m2 were successfully implanted and supported, indicating that this device may be appropriate for pediatric cases
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要